Department of Radiation Oncology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.
Centre for Neurooncology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.
Radiat Oncol. 2019 Dec 27;14(1):240. doi: 10.1186/s13014-019-1438-2.
As optic nerve sheath meningiomas (ONSM) are rare, there are no prospective studies. Our retrospective analysis focusses on a cohort of patients with uniform disease characteristics all treated with the same radiotherapy regimen. We describe treatment decision making, radiotherapy planning and detailed neuro-ophthalmological outcome of the patients.
26 patients with unilateral ONSM extending only to the orbit and the optic canal were evaluated for neuro-ophthalmological outcome. Radiation treatment was planned in a simultaneous integrated boost approach to gross tumor volume (GTV) + 2 mm / 5 mm to 54 Gy / 51 Gy in 1.8 Gy / 1.7 Gy fractions. Follow-up was done by specialized neuro-ophthalmologists. Visual acuity and visual field defects were evaluated after therapy as well as during follow-up.
Interdisciplinary treatment decision for patients with ONSM follows a rather complex decision tree. Radiation treatment planning (equivalent uniform dose (EUD), maximum dose to the optic nerve) improved with experience over time. With this patient selection visual acuity as well as visual field improved significantly at first follow-up after treatment. For visual acuity this also applied to patients with severe defects before treatment. Long term evaluation showed 16 patients with improved visual function, 6 were stable, in 4 patients visual function declined. Interdisciplinary case discussion rated the visual decline as radiation-associated in two patients.
With stringent patient selection radiotherapy for unilateral primary ONSM to 51 Gy / 54 Gy is safe and leads to significantly improved visual function. Interdisciplinary treatment decision and experience of the radiation oncology team play a major role.
由于视神经鞘脑膜瘤(ONSM)较为罕见,因此尚无前瞻性研究。我们的回顾性分析集中在一组具有统一疾病特征的患者,他们均接受相同的放射治疗方案治疗。我们描述了患者的治疗决策、放射治疗计划和详细的神经眼科结局。
我们评估了 26 例单侧仅向眼眶和视神经管延伸的 ONSM 患者的神经眼科结局。采用同步整合升压方法对大体肿瘤体积(GTV)+2mm/5mm 进行放射治疗,剂量为 54Gy/51Gy,1.8Gy/1.7Gy 分次。由专业的神经眼科医生进行随访。治疗后以及随访期间评估视力和视野缺损。
ONSM 患者的多学科治疗决策遵循一个相当复杂的决策树。随着时间的推移,放射治疗计划(等效均匀剂量(EUD),视神经最大剂量)的经验不断提高。通过这种患者选择,视力和视野在治疗后首次随访时显著改善。对于视力,这也适用于治疗前有严重缺陷的患者。长期评估显示,16 例患者的视觉功能改善,6 例稳定,4 例患者的视觉功能下降。多学科病例讨论认为,2 例患者的视力下降与放射有关。
对于单侧原发性 ONSM 进行 51Gy/54Gy 的放疗是安全的,并可显著改善视觉功能。多学科治疗决策和放射肿瘤学团队的经验起着重要作用。